2 Results for "

BCRP-mediated SN-38 resistance

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "BCRP-mediated SN-38 resistance" in MCE Product Catalog:

Cat. No.: HY-12758
CAS No.: 1346753-00-1
Purity:  99.16%
Target:  

BCRP

Research Areas:  

Cancer

YHO-13351 is an orally active ABCG2 inhibitor . YHO-13351 modulates the function of ABCG2, blocks BCRP-mediated compound efflux, downregulates the expression of breast cancer resistance protein at the post-transcriptional level, and reverses ABCG2-associated tolerance. YHO-13351 restores the toxicity of SN-38 to SN-38-resistant cancer cells and sensitizes cancer cells to Irinotecan. YHO-13351 is a water-soluble prodrug that is rapidly converted to YHO-13177 (HY-12757) in mice. YHO-13351 prolongs the median survival time of mice bearing cancer cell xenografts when combined with IMMU-132. YHO-13351 extends the survival time of tumor-bearing mice and inhibits the growth of xenograft tumors when combined with Irinotecan. YHO-13351 can be used for the research of breast cancer, gastric cancer, BCRP-mediated drug-resistant cancers, and cervical cancer .
loading...
    loading...
Cat. No.: HY-N17845
CAS No.: 87530-27-6
3,3'-Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxybibenzyl, a stilbenoid compound, is a tubulin inhibitor with an IC50 of 10 μM. 3,3'-Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxybibenzyl inhibits tubulin polymerization. 3,3'-Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxybibenzyl functions as a potentiator that potentiates SN-38 (HY-13704) cytotoxicity in BCRP-transduced cancer cells. 3,3'-Dihydroxy-2,6-bis(4-hydroxybenzyl)-5-methoxybibenzyl can be used for the study of breast cancer .
loading...
    loading...